AXM Pharma named distributor for Sygen in China
AXM Pharma, a US manufacturer of proprietary and generic pharmaceutical and nutraceutical products for the Chinese and other Asian markets, says that Brazil Wahsun Import & Export has signed a 10-year agreement, under which it has been designated exclusive distributor for Sygen, a product which is produced by TRB Pharma of Brazil.
Sygen measures pathological changes in the central nervous system and Parkinson's disease. AXM has entered into agreements with distributors from leading cities and provinces of Shanghai, Beijing, Guangdong, Jiangsu, Zhejiang and Shandong, to purchase a total quantity of 500,000 units, resulting in 2007 estimated revenue of $12,820,000.
Wang Weishi, chief executive of AXM, said: "Sygen has been extremely popular in international markets, and we are confident, based upon significant purchase orders from local distributors that it will be equally successful in China."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze